Bevacizumab

Autor Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
Vydáno 2010

Trastuzumab

Autor Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

Autor Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Vydáno 2009

Concise Drug Review: Azacitidine and Decitabine

Autor Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2013

Inhibitors of mTOR

Autor Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Vydáno 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2013

Lapatinib for Advanced or Metastatic Breast Cancer

Autor Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2012

Concise Drug Review: Pazopanib and Axitinib

Autor van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

Autor van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Vydáno 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

Autor Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Vydáno v Clin Pharmacokinet (2017)

Treatment Individualization in Colorectal Cancer

Autor van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
Vydáno v Curr Colorectal Cancer Rep (2015)

BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

Autor van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
Vydáno v Oncologist (2017)

Letter to the Editor Regarding “A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer” by Y...

Autor Mooiman, Kim D., Goey, Andrew K.L., Meijerman, Irma, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2012

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

Autor Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Vydáno 2012

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

Autor Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Vydáno 2011

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

Autor van Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno v Oncologist (2016)